Skip to Main Content

Author Details

Alice H Berger
Fred Hutchinson Cancer Research Center
2005
38
20
PMIDPaper TitleJournal TitlePublished Year
36712079Somatic mutation but not aneuploidy differentiates lung cancer in never-smokers and smokers.bioRxiv2023
36712079Somatic mutation but not aneuploidy differentiates lung cancer in never-smokers and smokers.bioRxiv2023
37396617pgMAP: a pipeline to enable guide RNA read mapping from dual-targeting CRISPR screens.ArXiv2023
37396617pgMAP: a pipeline to enable guide RNA read mapping from dual-targeting CRISPR screens.ArXiv2023
35058622Massively parallel phenotyping of coding variants in cancer with Perturb-seq.Nat Biotechnol2022
35512219All About That Ras: Novel Fusion Drives Ras Pathway Activation in Lung Cancer.Clin Cancer Res2022
35418694Correction to: Oncogenic RIT1 mutations in lung adenocarcinoma.Oncogene2022
36258042Author Correction: Massively parallel phenotyping of coding variants in cancer with Perturb-seq.Nat Biotechnol2022
35353015Cell Painting predicts impact of lung cancer variants.Mol Biol Cell2022
36522653Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer.BMC Cancer2022
35058622Massively parallel phenotyping of coding variants in cancer with Perturb-seq.Nat Biotechnol2022
35512219All About That Ras: Novel Fusion Drives Ras Pathway Activation in Lung Cancer.Clin Cancer Res2022
35353015Cell Painting predicts impact of lung cancer variants.Mol Biol Cell2022
35418694Correction to: Oncogenic RIT1 mutations in lung adenocarcinoma.Oncogene2022
36522653Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer.BMC Cancer2022
36258042Author Correction: Massively parallel phenotyping of coding variants in cancer with Perturb-seq.Nat Biotechnol2022
34373451Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer.Nat Commun2021
35419481Genome-wide CRISPR screening reveals novel therapeutic targets in RIT1-driven lung cancer.Mol Cell Oncol2021
34236315Loss of MGA repression mediated by an atypical polycomb complex promotes tumor progression and invasiveness.Elife2021
33626341Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.Cell Rep2021
33606973CRISPR base editor screens identify variant function at scale.Mol Cell2021
34469736Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome.Cell Rep2021
34846918Multiomic characterization of oncogenic signaling mediated by wild-type and mutant RIT1.Sci Signal2021
34373451Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer.Nat Commun2021
35419481Genome-wide CRISPR screening reveals novel therapeutic targets in RIT1-driven lung cancer.Mol Cell Oncol2021
33626341Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.Cell Rep2021
33606973CRISPR base editor screens identify variant function at scale.Mol Cell2021
34469736Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome.Cell Rep2021
34846918Multiomic characterization of oncogenic signaling mediated by wild-type and mutant RIT1.Sci Signal2021
34236315Loss of MGA repression mediated by an atypical polycomb complex promotes tumor progression and invasiveness.Elife2021
31911676RNA isoform screens uncover the essentiality and tumor-suppressor activity of ultraconserved poison exons.Nat Genet2020
31911676RNA isoform screens uncover the essentiality and tumor-suppressor activity of ultraconserved poison exons.Nat Genet2020
30475228Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis.J Clin Invest2019
31862013Recommendations for the collection and use of multiplexed functional data for clinical variant interpretation.Genome Med2019
30475228Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis.J Clin Invest2019
31862013Recommendations for the collection and use of multiplexed functional data for clinical variant interpretation.Genome Med2019
29625050Oncogenic Signaling Pathways in The Cancer Genome Atlas.Cell2018
29625050Oncogenic Signaling Pathways in The Cancer Genome Atlas.Cell2018
28522754<i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.Cancer Res2017
28522754<i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.Cancer Res2017
29195078A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.Cell2017
29232558High-throughput Phenotyping of Lung Cancer Somatic Mutations.Cancer Cell2017
29232558High-throughput Phenotyping of Lung Cancer Somatic Mutations.Cancer Cell2017
29195078A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.Cell2017
27158780Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.Nat Genet2016
27478040High-throughput Phenotyping of Lung Cancer Somatic Mutations.Cancer Cell2016
27158780Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.Nat Genet2016
27882345Institutional implementation of clinical tumor profiling on an unselected cancer population.JCI Insight2016
27882345Institutional implementation of clinical tumor profiling on an unselected cancer population.JCI Insight2016
27478040High-throughput Phenotyping of Lung Cancer Somatic Mutations.Cancer Cell2016
  • 1 - 50 of 76

Recommended Authors

Stanford University School of Medicine
Career Start Year 2013
Number of shared co-authors 0
McDermott Center for Human Growth and Development.
Career Start Year 2010
Number of shared co-authors 0
Ottawa Hospital Research Institute
Career Start Year 2010
Number of shared co-authors 0
Broad Institute of Harvard and MIT
Career Start Year 2010
Number of shared co-authors 11
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2009
Number of shared co-authors 0
Montefiore Medical Center
Career Start Year 2008
Number of shared co-authors 2
National Cancer Institute
Career Start Year 2008
Number of shared co-authors 21
Foundation Medicine Inc.
Career Start Year 2008
Number of shared co-authors 5
Laura and Isaac Perlmutter Cancer Center
Career Start Year 2007
Number of shared co-authors 8
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 40
University of Cologne, Faculty of Medicine and University Hospital Cologne
Career Start Year 2005
Number of shared co-authors 19
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 36
University of Toronto
Career Start Year 2005
Number of shared co-authors 2
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2003
Number of shared co-authors 0
The Francis Crick Institute
Career Start Year 2003
Number of shared co-authors 3
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 39
Stanford University School of Medicine
Career Start Year 2002
Number of shared co-authors 3
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2001
Number of shared co-authors 1
Monash University
Career Start Year 2000
Number of shared co-authors 5
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Wellcome Sanger Institute
Career Start Year 1998
Number of shared co-authors 13
University of California san francisco
Career Start Year 1998
Number of shared co-authors 8
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 22
McDermott Center for Human Growth and Development, UT Southwestern Medical Center
Career Start Year 1997
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute
Career Start Year 1995
Number of shared co-authors 0
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 10
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 21
Broad Institute of Harvard and MIT
Career Start Year 1990
Number of shared co-authors 28
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 7

Collaborators

Broad Institute
Co-authored papers 12
Co-authored papers 8
Co-authored papers 7
Broad Institute of Harvard and MIT
Co-authored papers 6
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 6
Co-authored papers 5
Co-authored papers 5
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 4
Co-authored papers 4
Fred Hutchinson Cancer Research Center, University of Washington
Co-authored papers 4
Co-authored papers 3
University of California san francisco
Co-authored papers 3
Dana-Farber Cancer Institute
Co-authored papers 3
Broad Institute of Harvard and MIT
Co-authored papers 3
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Broad Institute of MIT and Harvard
Co-authored papers 3
The Broad Institute of MIT and Harvard
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Broad Institute of Harvard and MIT
Co-authored papers 3
Co-authored papers 3
University of California San Diego
Co-authored papers 2
Broad Institute of MIT and Harvard
Co-authored papers 2
Weizmann Institute of Medical Sciences
Co-authored papers 2